New blood test can detect 'toxic' protein years before Alzheimer's symptoms emerge!

 | Post date: 2022/12/19 | 
Researchers at the University of Washington has developed a laboratory test that can measure levels of amyloid beta oligomers in blood samples. They showed The presence of α–sheet Aβ oligomers in plasma, as detected with SOBA, is highly correlated with Alzheimer's disease. They show that a designed α–sheet peptide inhibits the deleterious effects on neuronal signaling and also serves as a capture agent in our soluble oligomer binding assay (SOBA). Pre-incubated synthetic α–sheet-containing Aβ oligomers produce strong SOBA signals, while monomeric and β-sheet protofibrillar Aβ do not. α–sheet containing oligomers were also present in cerebrospinal fluid (CSF) from an AD patient versus a noncognitively impaired control. For the detection of toxic oligomers in plasma, they developed a plate coating to increase the density of the capture peptide. The proof of concept was achieved by testing 379 banked human plasma samples. SOBA detected Aβ oligomers in patients on the AD continuum, including controls who later progressed to mild cognitive impairment. In addition, SOBA discriminated AD from other forms of dementia, yielding sensitivity and specificity of 99% relative to clinical and neuropathological diagnoses. To explore the broader potential of SOBA, they adapted the assay for a-synuclein oligomers and confirmed their presence in CSF from patients with Parkinson’s disease and Lewy body dementia.
Read more



CAPTCHA

View: 61 Time(s)   |   Print: 9 Time(s)   |   Email: 0 Time(s)   |   0 Comment(s)


© 2023 CC BY-NC 4.0 | Modern Medical Laboratory Journal